What are the maternal and fetal risks associated with pregnancy in women with Ehlers‑Danlos syndrome?

Pregnancy Risks with Ehlers-Danlos Syndrome

Pregnancy risks in Ehlers-Danlos syndrome vary dramatically by subtype, with vascular EDS (type IV) representing a life-threatening contraindication to pregnancy due to risk of arterial and uterine rupture, while hypermobile EDS carries significant but non-lethal obstetric complications.

Critical Distinction by EDS Subtype

Vascular EDS (Type IV) - Highest Risk

Vascular EDS is considered a contraindication to pregnancy due to catastrophic maternal risks 1. The European Society of Cardiology guidelines explicitly state this based on mortality concerns.

Maternal risks in vascular EDS include:

• Arterial rupture and dissection - can occur even without aortic dilatation 1, 2
• Uterine rupture during pregnancy or delivery 1
• Large vessel rupture 1
• Extensive hemorrhage due to tissue fragility 1

However, recent prospective data challenges the absolute contraindication. Two 2025-2026 studies show no maternal deaths, arterial dissections, or uterine ruptures in women with confirmed vascular EDS who were diagnosed pre-pregnancy 3, 4. This suggests that with known diagnosis and careful selection, pregnancy may be safer than historically reported, though the evidence remains limited.

Common pitfall: The 2022 ACC/AHA guidelines note that women with specific genetic variants (particularly null mutations) and normal vascular imaging may have lower risk, making individualized counseling essential 2. The decision requires shared decision-making with a multidisciplinary team.

Hypermobile EDS and HSD - Moderate Risk

For hypermobile EDS (the most common type), pregnancy carries significant obstetric complications but not the catastrophic vascular risks seen in vascular EDS.

Maternal Complications (All EDS Types)

Obstetric complications include:

• Preterm birth - significantly increased risk 5, 6, 7
• Postpartum hemorrhage - elevated risk 4, 5
• Cervical incompetence - 3.11-fold increased risk 6
• Antepartum hemorrhage - 1.71-fold increased risk 6
• Placenta previa - 2.26-fold increased risk 6
• Severe perineal tears - common with vaginal delivery 4
• Cesarean section requirement - 1.55-fold increased risk 5, 6
• Prolonged hospital stays (>7 days postpartum) - 2.82-fold increased risk 6
• Increased bruising, hernias, and varicosities during pregnancy 1

Maternal mortality: While rare, maternal death risk is elevated 9.04-fold in EDS pregnancies overall 6. However, this appears concentrated in vascular EDS cases.

Fetal and Neonatal Risks

Fetal complications include:

• Intrauterine growth restriction (IUGR) - 1.81-fold increased risk 5, 6
• Preterm birth - consistently elevated across studies 5, 6, 7
• Miscarriage rate of 19% - particularly in women with glycine substitution variants in COL3A1 4
• Preterm premature rupture of membranes (PPROM) - especially when the fetus has EDS (38.9% vs 12.5% when only mother affected) 7

Important finding: Fetal EDS status appears to contribute more to certain poor outcomes (preterm birth, PPROM) than maternal EDS status alone 7. This suggests the fetal connective tissue disorder directly impacts pregnancy maintenance.

Management Approach

Pre-Pregnancy Evaluation

For vascular EDS:

• Imaging of entire aorta (CT/MRI) from head to pelvis 2
• Genetic counseling regarding 50% transmission risk
• Extensive counseling about maternal mortality risk
• Consider baseline surveillance of all arterial segments 2

For all EDS types:

• Cardiac evaluation including echocardiography
• Assessment for comorbidities (dysautonomia, mast cell disorders, chronic pain)
• Pelvic floor assessment

During Pregnancy

Monitoring frequency:

• High-risk obstetric care throughout pregnancy 8
• For vascular EDS with aortic involvement: echocardiography every 4-12 weeks 1
• Surveillance for preterm labor signs given elevated risk
• Serial growth ultrasounds for IUGR screening

Medical therapy:

• Beta-blockers may be considered in vascular EDS, though evidence is limited 2
• Celiprolol showed some benefit in non-pregnant vascular EDS patients but lacks FDA approval 2

Delivery Planning

Mode of delivery:

• Most women with known vascular EDS undergo cesarean delivery due to tissue fragility 2
• For hypermobile EDS, vaginal delivery is possible but carries increased risk of severe perineal tears 4
• Cesarean section rates are elevated across all EDS types 5, 6

Delivery considerations:

• Meticulous surgical technique if cesarean required due to tissue fragility and bleeding risk 2
• Anesthesia planning for joint hypermobility and potential autonomic dysfunction 8
• Prepare for postpartum hemorrhage risk

Postpartum Period

• Extended monitoring for wound healing complications
• Surveillance for postpartum hemorrhage
• Continued aortic monitoring for 6 months postpartum in vascular EDS 1
• Pelvic floor rehabilitation given tissue laxity

Evidence Quality and Evolving Understanding

The strongest guideline evidence 1 dates from 2011 and takes a conservative stance, particularly regarding vascular EDS. However, the most recent prospective data from 2025-2026 3, 4 shows zero maternal deaths or catastrophic vascular events in diagnosed women, suggesting current guidelines may be overly restrictive. This represents a significant shift in understanding, though the evidence base remains limited by small sample sizes.

For hypermobile EDS, the evidence consistently demonstrates elevated obstetric complications but manageable risks with appropriate high-risk obstetric care 5, 6, 8.